CA
ABOS icon

Clune & Associates’s Acumen Pharmaceuticals ABOS Stock Holding History

Clune & Associates’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.1K Hold
16,500
– – 0.01% 170
2026
Q1 		$38.9K Hold
16,500
– – 0.01% 162
2025
Q4 		$34.8K Hold
16,500
– – 0.01% 166
2025
Q3 		$28.2K Hold
16,500
– – 0.01% 159
2025
Q2 		$19.1K Hold
16,500
– – 0.01% 156
2025
Q1 		$18.1K Hold
16,500
– – 0.01% 141
2024
Q4 		$28.4K Buy
+16,500
New +$39.7K 0.01% 136

Other funds holding ABOS

PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Clune & Associates's ABOS Position: Q2 2026 in Review

Clune & Associates held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 16,500 shares worth $44.1K. The position accounts for 0.01% of the portfolio, ranked #170.

Clune & Associates first reported a position in ABOS in Q4 2024 and has held it in 7 quarters since. 4 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Clune & Associates held 16,500 shares of Acumen Pharmaceuticals worth $44.1K as of Q2 2026.
  • Clune & Associates left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
  • Acumen Pharmaceuticals made up 0.01% of Clune & Associates's portfolio in Q2 2026, its #170 holding.
  • Clune & Associates first reported a position in Acumen Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 4 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Clune & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.